Description
Anti-GD3 Ganglioside Antibody, Non-Fucosylated (BioBet-243ZP) is a chimeric monoclonal IgG1, κ antibody against GD3 Ganglioside. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Malignant melanoma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced GD3 Ganglioside antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
GD3 Ganglioside
Alternative Names
Ecromeximab; 292819-64-8; KW2871; KW-2871; KM871; GD3 ganglioside
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-243ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to GD3 ganglioside. Ecromeximab is a monoclonal antibody being developed for the treatment of malignant melanoma.
Antibody Indication
Malignant melanoma
